PROVE-HCC: A study for People with Liver Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to measure quality of life and compare signs such as tiredness, feeling of unease, discomfort in the stomach, and pain in patients who have been treated with either PLA or HIGRT for liver cancer.

What is the Condition Being Studied?

Liver cancer

Who Can Participate in the Study?

Adults who:

  • Are diagnosed with 1-3 liver tumors that are less than or equal to 5cm in size
  • Can be treated with either PLA or HIGRT
Age Group

What is Involved?

If you choose to join this study, you will get a random assignment (like drawing numbers from a hat) assigned to one of the following standard of care treatments:

  • Percutaneous Local Ablation (PLA) - This treatment involves inserting special needles into the liver and using microwaves or radiowaves to damage cancer cells in a way that may cause cell death.
  • Hypofractionated Image Guided Radiation Therapy (HIGRT) - In this treatment, beams of radiation enter the liver from multiple angles to treat the liver cancer over several treatment sessions (typically 5-10 treatments).

This study will last for about 8 months.

Study Details

Full Title
Phase II Non-Randomized Trial Comparing Interventional Radiology Liver Directed Therapies to Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients (PROVE-HCC)
Principal Investigator
Radiation Oncologist
Protocol Number
IRB: PRO00089525
NCT: NCT04933435
Phase II
Enrollment Status
Open for Enrollment